Medicenna Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Vancouver BC Canada (2015)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02858895
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Medicenna Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

mdna11 (1 trial)

mdna55 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2